The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
21 new analysts joined in June and are highlighted today. Each is introduced with some details on their first investment thesis on Seeking Alpha and their background. Analysts cover a range of sectors...
Short interest is high and rising in many stocks, setting them up for a squeeze given the proper catalyst. The catalyst for a squeeze could be as simple as Meme stock mania and result in quick gains f...
NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold...
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jeff...
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ub...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being unde...
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Presid...
TG Therapeutics (TGTX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.28 per share a year ago....
TG Therapeutics Inc is up 30% on Wednesday even though it reported a wider-than-expected per-share loss for its fiscal first quarter. Why is TG Therapeutics stock up today?...